Form 4: Cidara CMO Reports Merger-Related Stock Transactions

Cidara Therapeutics Chief Medical Officer Nicole Negar Davarpanah reported the disposition of common stock, restricted stock units, and employee stock options following the company's acquisition by Merck.

Summary

• Cidara Therapeutics, Inc. entered into an Agreement and Plan of Merger with Merck Sharp & Dohme LLC and Caymus Purchaser, Inc. on November 13, 2025.
• On January 7, 2026, Caymus Purchaser, Inc., a wholly-owned subsidiary of Merck, completed a tender offer to acquire all outstanding shares of Cidara Therapeutics, Inc.
• Following the tender offer, Caymus Purchaser, Inc. merged with and into Cidara Therapeutics, Inc., with Cidara continuing as the surviving corporation and a wholly-owned subsidiary of Merck.
• Common Shares were disposed of in exchange for $221.50 per share in cash.
• Series A Convertible Voting Preferred Stock was disposed of in exchange for $15,505.00 per share in cash.
• Outstanding restricted stock unit (RSU) awards were cancelled and converted into the right to receive cash, calculated as the total number of common shares issuable for the RSU multiplied by $221.50 per common share.
• Outstanding employee stock options became fully vested and exercisable, then were cancelled and converted into the right to receive cash, calculated as the total number of common shares subject to the option multiplied by the difference between $221.50 and the option's exercise price.
• Nicole Negar Davarpanah, Chief Medical Officer, disposed of 12,553 shares of Common Stock at $221.50 per share.
• Nicole Negar Davarpanah also disposed of 8,333 shares of Common Stock related to RSU awards.
• Additionally, Nicole Negar Davarpanah disposed of multiple employee stock options with exercise prices ranging from $10.75 to $21.75, totaling 128,597 options.

Sentiment

Score: 7

Explanation: The sentiment is positive for shareholders and option holders of Cidara Therapeutics due to the successful completion of the merger and the cash payout for their securities. However, the company itself ceases to exist as an independent entity.

Positives

• The completion of the merger provides immediate liquidity to all Cidara Therapeutics shareholders and holders of restricted stock units and employee stock options.
• Shareholders received a significant cash consideration of $221.50 per Common Share and $15,505.00 per Series A Preferred Share.
• Employee stock options became fully vested and were converted into cash, providing a payout based on the merger consideration exceeding their exercise prices.

Negatives

• Cidara Therapeutics, Inc. has ceased to be an independent publicly traded company, becoming a wholly-owned subsidiary of Merck.
• Former shareholders no longer have direct equity participation in Cidara's future growth or strategic direction.

Future Outlook

Cidara Therapeutics, Inc. has become a wholly-owned subsidiary of Merck Sharp & Dohme LLC, ceasing to operate as an independent publicly traded company. Its future operations will be integrated within Merck's structure.

Industry Context

The acquisition of Cidara Therapeutics by Merck is consistent with broader trends in the pharmaceutical and biotechnology sectors, where larger established companies often acquire smaller firms to expand their drug pipelines, gain access to innovative technologies, or eliminate competition. This particular transaction highlights the strategic value placed on Cidara's assets by a major player like Merck.

Comparison to Industry Standards

• The acquisition price of $221.50 per common share and $15,505.00 per Series A preferred share reflects the valuation agreed upon in the merger, which is typical for such transactions in the biotech space.
• While specific comparable company valuations are not provided, such premiums are often assessed against the target company's pre-announcement trading price and analyst price targets, indicating a strategic value for the acquiring entity, Merck.

Stakeholder Impact

• Shareholders: Received cash for their shares, gaining immediate liquidity but losing future upside potential from Cidara as an independent entity.
• Employees (including Chief Medical Officer): Employee stock options vested and converted to cash, providing a financial payout. Future employment status would be under Merck.
• Cidara Therapeutics, Inc.: Ceased independent public operations and became a wholly-owned subsidiary of Merck, integrating its assets and operations into the larger entity.

Key Dates

Keywords

Merger, Acquisition, Tender Offer, Common Stock, Preferred Stock, Stock Options, RSU, Insider Transaction, Beneficial Ownership, Cidara Therapeutics, Merck